Cerebral Venous Thrombosis: Causes, Symptoms & Treatment

Cerebral venous thrombosis (CVT) is a blood clot that forms in the veins or venous sinuses that drain blood from the brain. It accounts for roughly 0.5% to 3% of all strokes but behaves very differently from the arterial strokes most people picture. CVT tends to strike younger adults and women of childbearing age, and its symptoms can be maddeningly nonspecific, which means it often goes unrecognized until significant damage has occurred. Despite that, the prognosis is better than many other stroke types when caught and treated early.

How Common Is CVT and Who Gets It

Population studies put CVT incidence somewhere in the range of roughly 2 to 9 cases per million people per year, depending on the population studied and the surveillance methods used. A large British Columbia study covering 2000 to 2017 found an overall annual incidence of about 9 per million, with a mean patient age around 51 and a slight female majority.¹ A smaller US county-level study placed the rate higher, at roughly 2.3 per 100,000 person-years, with the highest rates in men over 65 and women aged 18 to 29.² The apparent discrepancy partly reflects methodological differences, but the takeaway is consistent: CVT is uncommon but not rare, and it clusters in two demographic windows, younger women (largely due to hormonal factors) and older men (where cancer and other systemic illness play a bigger role).

About three-quarters of cases have at least one identifiable predisposing factor, such as infection, active cancer, or oral contraceptive use.² That still leaves a meaningful fraction where no trigger is ever found, which is one of the reasons CVT remains a clinical challenge.

Why CVT Behaves Differently From an Arterial Stroke

In the more familiar kind of stroke, a clot blocks an artery carrying oxygen-rich blood into the brain. In CVT, the blockage sits on the outflow side, in the veins that carry blood away. That distinction matters because the brain’s venous system has extensive built-in detour routes. In the early stages of a venous blockage, blood can reroute through collateral channels, which is why symptoms sometimes build gradually over days or weeks rather than hitting all at once.³

When those backup routes become overwhelmed, venous pressure climbs. The consequences cascade: veins and capillaries become engorged, fluid leaks into surrounding brain tissue (edema), cerebrospinal fluid production goes up while its absorption goes down, and venous structures can eventually rupture, causing bleeding into the brain.³ This mix of swelling and hemorrhage is characteristic of CVT and explains why its imaging appearance can confuse clinicians expecting the clean-cut pattern of an arterial stroke.

Hormonal Causes and Why Young Women Are Overrepresented

Hormonal contraceptives are one of the strongest and most well-documented risk factors for CVT. A systematic review and meta-analysis found that women aged 15 to 50 who took oral contraceptive pills had roughly 7.6 times the odds of developing CVT compared with non-users.⁴ A more recent case-control study found the risk even higher for combined hormonal contraceptives overall, with an approximately 11-fold increase, and dramatically higher still for fourth-generation pills, where the odds ratio reached about 28.⁵ Higher estrogen doses increased the risk in a dose-dependent fashion, and even variable-dose formulations and progestin-only pills carried a roughly six-fold increase.⁵

The postpartum period is the other major hormonal window. A study comparing CVT patients to controls found that the risk was concentrated not during pregnancy itself but in the weeks after delivery. The first six weeks postpartum carried roughly a 19-fold increased risk, while pregnancy on its own showed no statistically significant elevation at all.⁶ That finding is worth knowing because many people assume the danger is during pregnancy; in reality, the weeks after delivery are the vulnerable period.

Inherited Clotting Disorders and Other Systemic Triggers

Thrombophilia, the tendency to form blood clots, plays a significant role in CVT and distinguishes it from ordinary arterial stroke. Factor V Leiden, one of the most common inherited clotting mutations, was found in about 17% of CVT patients compared with roughly 5% of healthy controls, giving an odds ratio close to 4. The prothrombin G20210A mutation was even more specific to CVT, appearing in about 15% of patients versus 3% of controls, with an odds ratio near 6. Strikingly, the prothrombin mutation was significantly more common in CVT than in arterial stroke, while Factor V Leiden was equally common in both.⁷ People who carry both mutations appear particularly vulnerable to CVT.

Beyond genetics, a broad range of conditions can set the stage. Active cancer is a well-recognized trigger because tumors release substances that promote clotting. Systemic infections, autoimmune diseases, and chronic inflammatory conditions raise the risk as well. Head and neck infections deserve special attention: ear infections (otitis media) and mastoiditis can spread to the nearby sigmoid sinus and cause clotting directly.⁸ This pathway was historically a major cause of CVT before widespread antibiotic use and remains relevant in pediatric cases or when ear infections go untreated.

Vaccine-Induced Immune Thrombotic Thrombocytopenia

During the COVID-19 pandemic, a rare syndrome called vaccine-induced immune thrombotic thrombocytopenia (VITT) brought CVT into public awareness. VITT was linked specifically to adenoviral vector-based vaccines and involved extreme activation of both platelets and the clotting system, leading to clots in unusual locations, including the brain’s venous sinuses, alongside a paradoxical drop in platelet count.⁹ The clinical course could be devastatingly rapid: one case series described five patients who developed CVT, brain hemorrhage, and low platelet counts one to two weeks after vaccination. Four of the five died despite maximal treatment.¹⁰

Autopsy studies found the thrombi in VITT cases were densely packed with white blood cells and showed signs of intense complement activation. The vaccine’s spike protein was detected within the thrombus material and the vessel wall itself.¹¹ VITT required a specific treatment approach: standard heparin was actually contraindicated because the immune mechanism resembled heparin-induced thrombocytopenia, and non-heparin anticoagulants plus intravenous immunoglobulin were used instead. VITT remains extremely rare, and the adenoviral vector vaccines most associated with it have largely been phased out of use, but the episode taught clinicians a great deal about atypical clotting mechanisms in the brain.

Symptoms and Why CVT Is Easy to Miss

The most common symptom is headache, which affects the vast majority of CVT patients but is also one of the most common complaints in all of medicine. In a study of headache patterns in CVT, onset was acute in about half of patients, subacute in roughly 43%, and thunderclap (maximum intensity within seconds) in only about 4%. The headache was spread across the whole head in about a third of cases and frontal in about 28%. In character, it was most often throbbing or aching.¹² A headache that progressively worsens over days or becomes widespread can serve as a marker for CVT, but nothing about the headache alone is definitive.

Beyond headache, the American Heart Association’s scientific statement notes that CVT presents with a diverse mix of neurological problems that can include seizures, focal weakness or numbness, vision changes, confusion, and decreased consciousness.¹³ The particular combination of symptoms depends on which sinus or vein is involved. Clots in the superior sagittal sinus, for example, often raise intracranial pressure and cause headache with papilledema and visual changes. Involvement of the lateral sinuses can mimic a brain tumor with focal deficits. This variability is exactly why CVT demands a high level of clinical suspicion: no single symptom points reliably to the diagnosis.

Diagnosis and the D-Dimer Dilemma

Imaging is the backbone of CVT diagnosis. Both CT venography and MR venography are considered adequate for confirming the diagnosis, though contrast-enhanced techniques perform better than non-contrast ones.¹⁴ When MR venography is used as the reference standard, CT venography shows sensitivity and specificity in the range of 75% to 100%, depending on which specific sinus is involved.¹⁵ In practice, which test you get often comes down to availability and the clinical situation; CT is faster and more widely accessible in emergency rooms, while MRI provides better detail of brain tissue damage.

D-dimer, the blood test widely used to screen for blood clots in the legs and lungs, has a complicated role in CVT. A meta-analysis of patients presenting with isolated headache found a D-dimer sensitivity of about 98% and a negative predictive value near 100%, which sounds reassuring.¹⁶ But there is an important catch: when the analysis included additional patients from non-consecutive series, sensitivity dropped to about 87%. And a separate study looking specifically at patients with confirmed CVT found that 10% had D-dimer levels below the standard cutoff, with isolated headache being the main predictor of a falsely negative result.¹⁷ Another study confirmed this pattern: two patients with confirmed CVT who had low D-dimer levels had headaches lasting more than 30 days.¹⁸

The practical implication is that a normal D-dimer can be falsely reassuring, particularly in people with a longstanding headache as their only symptom. If clinical suspicion is high, imaging should not be skipped just because the D-dimer comes back normal.

Treatment With Blood Thinners

Anticoagulation (blood-thinning medication) is the cornerstone of CVT treatment, even when there is bleeding in the brain, which is a counterintuitive but well-supported practice. A network analysis found that both low-molecular-weight heparin and unfractionated heparin outperformed placebo in CVT patients with hemorrhagic stroke, and low-molecular-weight heparin showed advantages over unfractionated heparin in that subgroup as well.¹⁹ The logic is that the bleeding is a consequence of venous congestion, and the best way to stop it from getting worse is to relieve the venous blockage by preventing the clot from growing.

After the acute phase, patients typically transition to oral anticoagulation for several months. Traditionally that meant warfarin, but direct oral anticoagulants (DOACs) have become increasingly popular. A large international multicenter study found that DOACs had a similar risk of recurrent blood clots, similar recanalization rates, and a similar death rate compared with warfarin, but with a significantly lower risk of major bleeding.²⁰ A comprehensive meta-analysis reached a similar conclusion about comparable safety and efficacy, noting that DOACs may be preferred for practical reasons since they don’t require regular blood monitoring the way warfarin does.²¹

When Blood Thinners Are Not Enough

A small but significant fraction of CVT patients deteriorate despite anticoagulation. For those cases, two escalation strategies exist: mechanical thrombectomy and decompressive surgery.

Mechanical thrombectomy involves threading a catheter into the blocked sinus and physically removing or breaking up the clot. A single-center retrospective study of 20 patients with severe or treatment-resistant CVT who underwent mechanical thrombectomy found that about 62% improved during the hospital stay and 80% had improved by six months, with 70% achieving complete recovery.²² These numbers are encouraging, but selection matters: the procedure is reserved for patients who are failing standard therapy, so the comparison group isn’t straightforward.

For the most dire scenario, where brain swelling threatens to push brain tissue into areas it doesn’t belong (herniation), decompressive hemicraniectomy can be lifesaving. This surgery involves temporarily removing a portion of the skull to give the swollen brain room to expand outward rather than downward. A prospective case series of 10 patients who were heading toward herniation despite maximal medical treatment found that 8 of 10 survived, and 5 recovered without disability at one year. Two patients had residual handicap, and two died from progressive swelling.²³ For patients whose prognosis with medical treatment alone would have been nearly hopeless, those outcomes are remarkable.

Long-Term Outcomes and Lingering Problems

On standardized disability scales, CVT outcomes look quite good. An analysis of 161 patients found that 84% scored in the range of no significant disability on the modified Rankin Scale at long-term follow-up. But that headline number obscures a more complicated reality: 42% of patients reported residual symptoms, and many were unable to return to their previous jobs.²⁴ The same study found that about 6% developed another venous blood clot (including recurrent CVT) during follow-up, and another 6% had a serious bleeding event, most likely related to their ongoing anticoagulation.

Despite intensive treatment, death or dependence still occurs in roughly 10% to 15% of patients.¹³ The people who do worst tend to be those with coma at presentation, large hemorrhagic infarcts, cancer as the underlying cause, or deep venous system involvement rather than the more superficial sinuses.

CVT in Children and Newborns

CVT is not exclusively an adult disease. A large Canadian registry found an incidence of about 0.67 per 100,000 children per year, with newborns being the most commonly affected age group. The presentation in children looks different from adults: 58% had seizures, 76% had diffuse neurological signs, and 42% had focal deficits. Risk factors were a mix of head and neck problems (29%), acute systemic illness (54%), chronic disease (36%), and inherited clotting tendencies (41%). Venous infarcts occurred in 41%, and 8% died, with half of those deaths directly attributable to the clot.²⁵

Treating children with anticoagulants raises understandable anxiety, particularly in newborns. A safety study of 162 pediatric patients found that major hemorrhage occurred in about 6% of those treated with anticoagulants, including a higher rate (14%) in those who already had bleeding before treatment started. All the anticoagulant-associated bleeds were nonfatal. Perhaps more importantly, children who did not receive anticoagulants had significantly higher rates of clot progression: 28% of untreated neonates showed the clot growing on follow-up imaging, compared with only 4% of those on treatment.²⁶ European guidelines recommend considering anticoagulation in children during the acute phase and tailoring the treatment duration, typically three to six months, based on the child’s individual risk profile. For neonates, the decision is made on a case-by-case basis, with treatment durations generally shorter, around six to twelve weeks.²⁷

Cognitive and Emotional Aftereffects

Standard outcome scales used in stroke research focus on physical disability: can you walk, dress yourself, live independently? By those measures, most CVT survivors do well. But those scales miss cognitive and emotional problems that can reshape a person’s daily life just as profoundly. A two-center study found that cognitive impairment persisted in about a third of CVT survivors, with deficits spanning multiple thinking domains including attention, memory, and executive function.²⁸ Some patients scored perfectly well on the basic disability scale yet still had measurable impairment in psychosocial functioning and quality of life. Depression is another underrecognized problem: one study found that patients who had worse disability scores at hospital discharge were more likely to develop depression, but even patients with good physical recovery showed impaired psychosocial functioning.²⁹

These findings have real implications for follow-up care. A person who has recovered from CVT and looks fine on a standard neurological exam may still be struggling with concentration, word-finding, fatigue, or mood changes. Asking about those problems specifically, rather than waiting for the patient to bring them up, is where follow-up care often falls short. Neuropsychological testing and screening for depression deserve a place in the recovery plan, not as a luxury, but as a recognition that physical independence is not the same as full recovery.